Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A02243 | Pages: 233 | Charts: 59 | Tables: 157 |
The global clinical trial management market was valued at $969.4 million in 2020, and is projected to reach $2,810.5 million by 2030, registering a CAGR of 11.2% from 2021 to 2030. A clinical trial management system (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials. The system aims to manage and maintain tracking of patient data. Clinical trial management systems incorporate different components consisting of software, hardware, and services. Clinical trial management system provides data to business intelligence system, which acts as access centralized data, thus reducing the number of delayed trials.
[COVIDIMPACTSTATEMENT]
Growth of the global clinical trial management market is majorly driven by increase in industry academic collaborations, rise in number of clinical trials, growth in technology in the healthcare sector, and increase in government support for research trials. In addition, growth in number of clinical trial management system (CTMS) is attributed to factors such as high prevalence of chronic diseases.
Get more information on this report : Request Sample Pages
Furthermore, products of clinical trial management system are efficient, easy to use, provide effective patient safety and regulatory compliances, and enhance financial management. For instance, in December 2020, Environmental Response Team (ERT), a global company specializing in clinical services, announced the launch of data insight to enhance the study effectiveness and efficiency. Moreover, in January 2020, Veeva, a cloud computing company, announced the launch of veeva vault payment software, which is an application used for veeva vault CTMS. Growth in number of clinical trials and increase in number of key players to develop advanced clinical trial management system (CTMS) solution drive growth of the market.
[TYPEGRAPH]
The global clinical trial management market is segmented on the basis of type, delivery mode, component, and end user, and region. By type, the market is categorized into enterprise-based and site-based. On the basis of component, it is divided into software and service. By end user, it is divided into pharmaceutical & biopharmaceutical companies, clinical research organizations, and healthcare providers. Region wise, the clinical trial management market is divided into North America, Europe, Asia-Pacific, and LAMEA.
Depending on type, the enterprise-based segment was the highest contributor to the market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in technology in the healthcare sector, and initiatives taken by organizations to develop the healthcare sector.
[DELIVERYMODEGRAPH]
However, the site-based segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic diseases, rise in adoption of new technologies in clinical trials, and increase in demand of site-based clinical trial management system.
By delivery mode, the web-based segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in demand for web-based CTMS and increase in number of clinical trials. Web-based clinical trial management system (CTMS) possess advantages such as it enhances quality and productivity of clinical trials, provides better time management, and ease of access. However, the cloud-based segment is expected to witness considerable growth during the forecast period, owing to advancements in technology in the healthcare sector and surge in adoption of cloud-based system.
[COMPONENTGRAPH]
By component, the software segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to availability of advanced software, development in medical software, and increase in patient population. However, the services segment is expected to witness considerable growth during the forecast period, owing to increase in number of clinical trials and growth of the healthcare insurance industry.
By end user, the pharmaceutical & biopharmaceutical companies segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to development of pharmaceutical and biopharmaceutical companies and initiatives taken by government and private organizations to develop the pharmaceutical industry. However, the clinical research organizations segment is expected to witness considerable growth during the forecast period, owing to rise in prevalence of chronic and rare diseases, increase in number of clinical trials, and increase in investments in R&D activities in the pharmaceutical and biopharmaceutical sector.
[ENDUSERGRAPH]
North America garnered a major share in the clinical trial management market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of chronic diseases, increase in presence of key players to develop advanced software, and development in R&D activities in the healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 13.4% from 2021 to 2030, owing to increase in funds from government and private organizations to support clinical trials and increase in number of clinical trials.
Key players operating in the global clinical trial management market include Advarra, Inc., Clario, Deloitte Touche Tohmatsu Limited, IBM Corporation, Medideta Solution Inc., Mednet Solution Inc., Oracle Corporation, PAREXEL International Corporation, Thermo Fisher Scientific, Inc., and Veeva System Inc.
[REGIONGRAPH]
Key Benefits For Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1.Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis
CHAPTER 4:CLINICAL TRIAL MANAGEMENT MARKET, BY TYPE
4.1.Market Overview
4.1.1Market Size and Forecast, By Type
4.2.Enterprise Based
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.3.Site Based
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
CHAPTER 5:CLINICAL TRIAL MANAGEMENT MARKET, BY DELIVERY MODE
5.1.Market Overview
5.1.1Market Size and Forecast, By Delivery Mode
5.2.Web-based CTMS
5.2.1.Key Market Trends, Growth Factors and Opportunities
5.2.2.Market Size and Forecast, By Region
5.2.3.Market Share Analysis, By Country
5.3.On-premise
5.3.1.Key Market Trends, Growth Factors and Opportunities
5.3.2.Market Size and Forecast, By Region
5.3.3.Market Share Analysis, By Country
5.4.Cloud Based
5.4.1.Key Market Trends, Growth Factors and Opportunities
5.4.2.Market Size and Forecast, By Region
5.4.3.Market Share Analysis, By Country
CHAPTER 6:CLINICAL TRIAL MANAGEMENT MARKET, BY COMPONENT
6.1.Market Overview
6.1.1Market Size and Forecast, By Component
6.2.Software
6.2.1.Key Market Trends, Growth Factors and Opportunities
6.2.2.Market Size and Forecast, By Region
6.2.3.Market Share Analysis, By Country
6.3.Services
6.3.1.Key Market Trends, Growth Factors and Opportunities
6.3.2.Market Size and Forecast, By Region
6.3.3.Market Share Analysis, By Country
CHAPTER 7:CLINICAL TRIAL MANAGEMENT MARKET, BY END USERS
7.1.Market Overview
7.1.1Market Size and Forecast, By End Users
7.2.Pharmaceutical And Biopharmaceutical Companies
7.2.1.Key Market Trends, Growth Factors and Opportunities
7.2.2.Market Size and Forecast, By Region
7.2.3.Market Share Analysis, By Country
7.3.Clinical Research Organization
7.3.1.Key Market Trends, Growth Factors and Opportunities
7.3.2.Market Size and Forecast, By Region
7.3.3.Market Share Analysis, By Country
7.4.Healthcare Providers
7.4.1.Key Market Trends, Growth Factors and Opportunities
7.4.2.Market Size and Forecast, By Region
7.4.3.Market Share Analysis, By Country
CHAPTER 8:CLINICAL TRIAL MANAGEMENT MARKET, BY REGION
8.1.Market Overview
8.1.1Market Size and Forecast, By Region
8.2.North America
8.2.1.Key Market Trends and Opportunities
8.2.2.Market Size and Forecast, By Type
8.2.3.Market Size and Forecast, By Delivery Mode
8.2.4.Market Size and Forecast, By Component
8.2.5.Market Size and Forecast, By End Users
8.2.6.Market Size and Forecast, By Country
8.2.7.United States Clinical Trial Management Market
8.2.7.1.Market Size and Forecast, By Type
8.2.7.2.Market Size and Forecast, By Delivery Mode
8.2.7.3.Market Size and Forecast, By Component
8.2.7.4.Market Size and Forecast, By End Users
8.2.8.Canada Clinical Trial Management Market
8.2.8.1.Market Size and Forecast, By Type
8.2.8.2.Market Size and Forecast, By Delivery Mode
8.2.8.3.Market Size and Forecast, By Component
8.2.8.4.Market Size and Forecast, By End Users
8.2.9.Mexico Clinical Trial Management Market
8.2.9.1.Market Size and Forecast, By Type
8.2.9.2.Market Size and Forecast, By Delivery Mode
8.2.9.3.Market Size and Forecast, By Component
8.2.9.4.Market Size and Forecast, By End Users
8.3.Europe
8.3.1.Key Market Trends and Opportunities
8.3.2.Market Size and Forecast, By Type
8.3.3.Market Size and Forecast, By Delivery Mode
8.3.4.Market Size and Forecast, By Component
8.3.5.Market Size and Forecast, By End Users
8.3.6.Market Size and Forecast, By Country
8.3.7.France Clinical Trial Management Market
8.3.7.1.Market Size and Forecast, By Type
8.3.7.2.Market Size and Forecast, By Delivery Mode
8.3.7.3.Market Size and Forecast, By Component
8.3.7.4.Market Size and Forecast, By End Users
8.3.8.Germany Clinical Trial Management Market
8.3.8.1.Market Size and Forecast, By Type
8.3.8.2.Market Size and Forecast, By Delivery Mode
8.3.8.3.Market Size and Forecast, By Component
8.3.8.4.Market Size and Forecast, By End Users
8.3.9.Italy Clinical Trial Management Market
8.3.9.1.Market Size and Forecast, By Type
8.3.9.2.Market Size and Forecast, By Delivery Mode
8.3.9.3.Market Size and Forecast, By Component
8.3.9.4.Market Size and Forecast, By End Users
8.3.10.Spain Clinical Trial Management Market
8.3.10.1.Market Size and Forecast, By Type
8.3.10.2.Market Size and Forecast, By Delivery Mode
8.3.10.3.Market Size and Forecast, By Component
8.3.10.4.Market Size and Forecast, By End Users
8.3.11.U.K Clinical Trial Management Market
8.3.11.1.Market Size and Forecast, By Type
8.3.11.2.Market Size and Forecast, By Delivery Mode
8.3.11.3.Market Size and Forecast, By Component
8.3.11.4.Market Size and Forecast, By End Users
8.3.12.Rest Of Europe Clinical Trial Management Market
8.3.12.1.Market Size and Forecast, By Type
8.3.12.2.Market Size and Forecast, By Delivery Mode
8.3.12.3.Market Size and Forecast, By Component
8.3.12.4.Market Size and Forecast, By End Users
8.4.Asia-Pacific
8.4.1.Key Market Trends and Opportunities
8.4.2.Market Size and Forecast, By Type
8.4.3.Market Size and Forecast, By Delivery Mode
8.4.4.Market Size and Forecast, By Component
8.4.5.Market Size and Forecast, By End Users
8.4.6.Market Size and Forecast, By Country
8.4.7.China Clinical Trial Management Market
8.4.7.1.Market Size and Forecast, By Type
8.4.7.2.Market Size and Forecast, By Delivery Mode
8.4.7.3.Market Size and Forecast, By Component
8.4.7.4.Market Size and Forecast, By End Users
8.4.8.Japan Clinical Trial Management Market
8.4.8.1.Market Size and Forecast, By Type
8.4.8.2.Market Size and Forecast, By Delivery Mode
8.4.8.3.Market Size and Forecast, By Component
8.4.8.4.Market Size and Forecast, By End Users
8.4.9.India Clinical Trial Management Market
8.4.9.1.Market Size and Forecast, By Type
8.4.9.2.Market Size and Forecast, By Delivery Mode
8.4.9.3.Market Size and Forecast, By Component
8.4.9.4.Market Size and Forecast, By End Users
8.4.10.South Korea Clinical Trial Management Market
8.4.10.1.Market Size and Forecast, By Type
8.4.10.2.Market Size and Forecast, By Delivery Mode
8.4.10.3.Market Size and Forecast, By Component
8.4.10.4.Market Size and Forecast, By End Users
8.4.11.Australia Clinical Trial Management Market
8.4.11.1.Market Size and Forecast, By Type
8.4.11.2.Market Size and Forecast, By Delivery Mode
8.4.11.3.Market Size and Forecast, By Component
8.4.11.4.Market Size and Forecast, By End Users
8.4.12.Rest of Asia Pacific Clinical Trial Management Market
8.4.12.1.Market Size and Forecast, By Type
8.4.12.2.Market Size and Forecast, By Delivery Mode
8.4.12.3.Market Size and Forecast, By Component
8.4.12.4.Market Size and Forecast, By End Users
8.5.LAMEA
8.5.1.Key Market Trends and Opportunities
8.5.2.Market Size and Forecast, By Type
8.5.3.Market Size and Forecast, By Delivery Mode
8.5.4.Market Size and Forecast, By Component
8.5.5.Market Size and Forecast, By End Users
8.5.6.Market Size and Forecast, By Country
8.5.7.Brazil Clinical Trial Management Market
8.5.7.1.Market Size and Forecast, By Type
8.5.7.2.Market Size and Forecast, By Delivery Mode
8.5.7.3.Market Size and Forecast, By Component
8.5.7.4.Market Size and Forecast, By End Users
8.5.8.South Africa, Clinical Trial Management Market
8.5.8.1.Market Size and Forecast, By Type
8.5.8.2.Market Size and Forecast, By Delivery Mode
8.5.8.3.Market Size and Forecast, By Component
8.5.8.4.Market Size and Forecast, By End Users
8.5.9.Saudi Arabia Clinical Trial Management Market
8.5.9.1.Market Size and Forecast, By Type
8.5.9.2.Market Size and Forecast, By Delivery Mode
8.5.9.3.Market Size and Forecast, By Component
8.5.9.4.Market Size and Forecast, By End Users
8.5.10.Rest of LAMEA Clinical Trial Management Market
8.5.10.1.Market Size and Forecast, By Type
8.5.10.2.Market Size and Forecast, By Delivery Mode
8.5.10.3.Market Size and Forecast, By Component
8.5.10.4.Market Size and Forecast, By End Users
CHAPTER 9:COMPANY PROFILES
9.1.Advarra, Inc
9.1.1.Company Overview
9.1.2.Key Executives
9.1.3.Company snapshot
9.1.4.Operating business segments
9.1.5.Product portfolio
9.1.6.Business Performance
9.1.7.Key Strategic Moves and Developments
9.2.Clario
9.2.1.Company Overview
9.2.2.Key Executives
9.2.3.Company snapshot
9.2.4.Operating business segments
9.2.5.Product portfolio
9.2.6.Business Performance
9.2.7.Key Strategic Moves and Developments
9.3.Deloitte Touche Tohmatsu Limited
9.3.1.Company Overview
9.3.2.Key Executives
9.3.3.Company snapshot
9.3.4.Operating business segments
9.3.5.Product portfolio
9.3.6.Business Performance
9.3.7.Key Strategic Moves and Developments
9.4.IBM Corporation
9.4.1.Company Overview
9.4.2.Key Executives
9.4.3.Company snapshot
9.4.4.Operating business segments
9.4.5.Product portfolio
9.4.6.Business Performance
9.4.7.Key Strategic Moves and Developments
9.5.Medideta Solution Inc.
9.5.1.Company Overview
9.5.2.Key Executives
9.5.3.Company snapshot
9.5.4.Operating business segments
9.5.5.Product portfolio
9.5.6.Business Performance
9.5.7.Key Strategic Moves and Developments
9.6.Mednet Solution Inc.
9.6.1.Company Overview
9.6.2.Key Executives
9.6.3.Company snapshot
9.6.4.Operating business segments
9.6.5.Product portfolio
9.6.6.Business Performance
9.6.7.Key Strategic Moves and Developments
9.7.Oracle Corporation
9.7.1.Company Overview
9.7.2.Key Executives
9.7.3.Company snapshot
9.7.4.Operating business segments
9.7.5.Product portfolio
9.7.6.Business Performance
9.7.7.Key Strategic Moves and Developments
9.8.PAREXEL International Corporation
9.8.1.Company Overview
9.8.2.Key Executives
9.8.3.Company snapshot
9.8.4.Operating business segments
9.8.5.Product portfolio
9.8.6.Business Performance
9.8.7.Key Strategic Moves and Developments
9.9.Thermo Fisher Scientific, Inc
9.9.1.Company Overview
9.9.2.Key Executives
9.9.3.Company snapshot
9.9.4.Operating business segments
9.9.5.Product portfolio
9.9.6.Business Performance
9.9.7.Key Strategic Moves and Developments
9.10.Veeva System Inc
9.10.1.Company Overview
9.10.2.Key Executives
9.10.3.Company snapshot
9.10.4.Operating business segments
9.10.5.Product portfolio
9.10.6.Business Performance
9.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 2.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR ENTERPRISE BASED, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR SITE BASED, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 5.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR WEB-BASED CTMS, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR ON-PREMISE, BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR CLOUD BASED, BY REGION, 2020-2030 ($MILLION)
TABLE 8.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 9.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR SERVICES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET, BY END USERS, 2020-2030 ($MILLION)
TABLE 12.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR CLINICAL RESEARCH ORGANIZATION, BY REGION, 2020-2030 ($MILLION)
TABLE 14.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16.NORTH AMERICA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 20.UNITED STATES CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 21.UNITED STATES CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 22.UNITED STATES CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 23.UNITED STATES CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 24.CANADA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 25.CANADA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 26.CANADA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 27.CANADA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 28.MEXICO CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 30.MEXICO CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 31.MEXICO CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 32.EUROPE CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 33.EUROPE CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 34.EUROPE CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 35.EUROPE CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 36.FRANCE CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 37.FRANCE CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 38.FRANCE CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 39.FRANCE CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 40.GERMANY CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 41.GERMANY CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 42.GERMANY CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 43.GERMANY CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 44.ITALY CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 46.ITALY CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 47.ITALY CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 48.SPAIN CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 49.SPAIN CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 50.SPAIN CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 51.SPAIN CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 52.UNITED KINGDOM CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 53.UNITED KINGDOM CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 54.UNITED KINGDOM CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 55.UNITED KINGDOM CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 56.REST OF EUROPE CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 57.REST OF EUROPE CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 58.REST OF EUROPE CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 59.REST OF EUROPE CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 60.ASIA-PACIFIC CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 61.ASIA-PACIFIC CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 62.ASIA-PACIFIC CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 63.ASIA-PACIFIC CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 64.CHINA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 65.CHINA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 66.CHINA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 67.CHINA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 68.JAPAN CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 69.JAPAN CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 70.JAPAN CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 71.JAPAN CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 72.INDIA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 73.INDIA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 74.INDIA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 75.INDIA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 76.SOUTH KOREA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 77.SOUTH KOREA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 78.SOUTH KOREA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 79.SOUTH KOREA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 80.AUSTRALIA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 81.AUSTRALIA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 82.AUSTRALIA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 83.AUSTRALIA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 84.REST OF ASIA PACIFIC CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 85.REST OF ASIA PACIFIC CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 86.REST OF ASIA PACIFIC CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 87.REST OF ASIA PACIFIC CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 88.LAMEA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 89.LAMEA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 90.LAMEA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 91.LAMEA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 92.BRAZIL CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 93.BRAZIL CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 94.BRAZIL CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 95.BRAZIL CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 96.SOUTH AFRICA, CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 97.SOUTH AFRICA, CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 98.SOUTH AFRICA, CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 99.SOUTH AFRICA, CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 100.SAUDI ARABIA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 101.SAUDI ARABIA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 102.SAUDI ARABIA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 103.SAUDI ARABIA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 104.REST OF LAMEA CLINICAL TRIAL MANAGEMENT, BY TYPE, 2020-2030 ($MILLION)
TABLE 105.REST OF LAMEA CLINICAL TRIAL MANAGEMENT, BY DELIVERY MODE, 2020-2030 ($MILLION)
TABLE 106.REST OF LAMEA CLINICAL TRIAL MANAGEMENT, BY COMPONENT, 2020-2030 ($MILLION)
TABLE 107.REST OF LAMEA CLINICAL TRIAL MANAGEMENT, BY END USERS, 2020-2030 ($MILLION)
TABLE 108.ADVARRA, INC: KEY EXECUTIVES
TABLE 109.ADVARRA, INC: COMPANY SNAPSHOT
TABLE 110.ADVARRA, INC: OPERATING SEGMENTS
TABLE 111.ADVARRA, INC: PRODUCT PORTFOLIO
TABLE 112.ADVARRA, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.CLARIO: KEY EXECUTIVES
TABLE 114.CLARIO: COMPANY SNAPSHOT
TABLE 115.CLARIO: OPERATING SEGMENTS
TABLE 116.CLARIO: PRODUCT PORTFOLIO
TABLE 117.CLARIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.DELOITTE TOUCHE TOHMATSU LIMITED: KEY EXECUTIVES
TABLE 119.DELOITTE TOUCHE TOHMATSU LIMITED: COMPANY SNAPSHOT
TABLE 120.DELOITTE TOUCHE TOHMATSU LIMITED: OPERATING SEGMENTS
TABLE 121.DELOITTE TOUCHE TOHMATSU LIMITED: PRODUCT PORTFOLIO
TABLE 122.DELOITTE TOUCHE TOHMATSU LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123.IBM CORPORATION: KEY EXECUTIVES
TABLE 124.IBM CORPORATION: COMPANY SNAPSHOT
TABLE 125.IBM CORPORATION: OPERATING SEGMENTS
TABLE 126.IBM CORPORATION: PRODUCT PORTFOLIO
TABLE 127.IBM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128.MEDIDETA SOLUTION INC.: KEY EXECUTIVES
TABLE 129.MEDIDETA SOLUTION INC.: COMPANY SNAPSHOT
TABLE 130.MEDIDETA SOLUTION INC.: OPERATING SEGMENTS
TABLE 131.MEDIDETA SOLUTION INC.: PRODUCT PORTFOLIO
TABLE 132.MEDIDETA SOLUTION INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 133.MEDNET SOLUTION INC.: KEY EXECUTIVES
TABLE 134.MEDNET SOLUTION INC.: COMPANY SNAPSHOT
TABLE 135.MEDNET SOLUTION INC.: OPERATING SEGMENTS
TABLE 136.MEDNET SOLUTION INC.: PRODUCT PORTFOLIO
TABLE 137.MEDNET SOLUTION INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 138.ORACLE CORPORATION: KEY EXECUTIVES
TABLE 139.ORACLE CORPORATION: COMPANY SNAPSHOT
TABLE 140.ORACLE CORPORATION: OPERATING SEGMENTS
TABLE 141.ORACLE CORPORATION: PRODUCT PORTFOLIO
TABLE 142.ORACLE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143.PAREXEL INTERNATIONAL CORPORATION: KEY EXECUTIVES
TABLE 144.PAREXEL INTERNATIONAL CORPORATION: COMPANY SNAPSHOT
TABLE 145.PAREXEL INTERNATIONAL CORPORATION: OPERATING SEGMENTS
TABLE 146.PAREXEL INTERNATIONAL CORPORATION: PRODUCT PORTFOLIO
TABLE 147.PAREXEL INTERNATIONAL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 148.THERMO FISHER SCIENTIFIC, INC: KEY EXECUTIVES
TABLE 149.THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT
TABLE 150.THERMO FISHER SCIENTIFIC, INC: OPERATING SEGMENTS
TABLE 151.THERMO FISHER SCIENTIFIC, INC: PRODUCT PORTFOLIO
TABLE 152.THERMO FISHER SCIENTIFIC, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153.VEEVA SYSTEM INC: KEY EXECUTIVES
TABLE 154.VEEVA SYSTEM INC: COMPANY SNAPSHOT
TABLE 155.VEEVA SYSTEM INC: OPERATING SEGMENTS
TABLE 156.VEEVA SYSTEM INC: PRODUCT PORTFOLIO
TABLE 157.VEEVA SYSTEM INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET SEGMENTATION
FIGURE 2.GLOBAL CLINICAL TRIAL MANAGEMENT MARKET
FIGURE 3.SEGMENTATION CLINICAL TRIAL MANAGEMENT MARKET
FIGURE 4.TOP INVESTMENT POCKET IN CLINICAL TRIAL MANAGEMENT MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: CLINICAL TRIAL MANAGEMENT MARKET
FIGURE 16.CLINICAL TRIAL MANAGEMENT MARKET SEGMENTATION, BY TYPE
FIGURE 17.CLINICAL TRIAL MANAGEMENT MARKET FOR ENTERPRISE BASED, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.CLINICAL TRIAL MANAGEMENT MARKET FOR SITE BASED, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.CLINICAL TRIAL MANAGEMENT MARKET SEGMENTATION, BY DELIVERY MODE
FIGURE 20.CLINICAL TRIAL MANAGEMENT MARKET FOR WEB-BASED CTMS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.CLINICAL TRIAL MANAGEMENT MARKET FOR ON-PREMISE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.CLINICAL TRIAL MANAGEMENT MARKET FOR CLOUD BASED, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 23.CLINICAL TRIAL MANAGEMENT MARKET SEGMENTATION, BY COMPONENT
FIGURE 24.CLINICAL TRIAL MANAGEMENT MARKET FOR SOFTWARE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.CLINICAL TRIAL MANAGEMENT MARKET FOR SERVICES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.CLINICAL TRIAL MANAGEMENT MARKET SEGMENTATION, BY END USERS
FIGURE 27.CLINICAL TRIAL MANAGEMENT MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 28.CLINICAL TRIAL MANAGEMENT MARKET FOR CLINICAL RESEARCH ORGANIZATION, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 29.CLINICAL TRIAL MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 30.ADVARRA, INC: NET SALES, 2018-2020 ($MILLION)
FIGURE 31.ADVARRA, INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32.ADVARRA, INC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 33.CLARIO: NET SALES, 2018-2020 ($MILLION)
FIGURE 34.CLARIO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 35.CLARIO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 36.DELOITTE TOUCHE TOHMATSU LIMITED: NET SALES, 2018-2020 ($MILLION)
FIGURE 37.DELOITTE TOUCHE TOHMATSU LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 38.DELOITTE TOUCHE TOHMATSU LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 39.IBM CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 40.IBM CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.IBM CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 42.MEDIDETA SOLUTION INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 43.MEDIDETA SOLUTION INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 44.MEDIDETA SOLUTION INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 45.MEDNET SOLUTION INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 46.MEDNET SOLUTION INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 47.MEDNET SOLUTION INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 48.ORACLE CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 49.ORACLE CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 50.ORACLE CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 51.PAREXEL INTERNATIONAL CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 52.PAREXEL INTERNATIONAL CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 53.PAREXEL INTERNATIONAL CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 54.THERMO FISHER SCIENTIFIC, INC: NET SALES, 2018-2020 ($MILLION)
FIGURE 55.THERMO FISHER SCIENTIFIC, INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 56.THERMO FISHER SCIENTIFIC, INC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 57.VEEVA SYSTEM INC: NET SALES, 2018-2020 ($MILLION)
FIGURE 58.VEEVA SYSTEM INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 59.VEEVA SYSTEM INC: REVENUE SHARE, BY REGION, 2020 (%)